Jpmorgan Chase & CO Annexon, Inc. Transaction History

Jpmorgan Chase & CO

$1.1 Trillion
Q1 2024

A detailed history of Jpmorgan Chase & CO transactions in Annexon, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 959,648 shares of ANNX stock, worth $4.64 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

959,648

Previous 29,585 3143.7%

Holding current value

$4.64 Million

Previous $134,000 5034.33%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$4.03 - $7.81 $3.75 Million - $7.26 Million	930,063 Added 3143.7%	959,648 $6.88 Million
Q4 2023 Feb 12, 2024	SELL	$1.63 - $4.63 $16,355 - $46,457	-10,034 Reduced 25.33%	29,585 $134,000
Q3 2023 Nov 14, 2023	BUY	$2.13 - $3.84 $3,148 - $5,675	1,478 Added 3.88%	39,619 $93,000
Q2 2023 Aug 11, 2023	BUY	$2.1 - $6.37 $76,488 - $232,014	36,423 Added 2120.08%	38,141 $134,000
Q1 2023 May 11, 2023	SELL	$3.74 - $7.46 $112,214 - $223,829	-30,004 Reduced 94.58%	1,718 $6,000

Q4 2022 Feb 13, 2023	BUY	$4.56 - $6.02 $26,019 - $34,350	5,706 Added 21.93%	31,722 $164,000
Q3 2022 Nov 14, 2022	SELL	$3.75 - $6.63 $627,063 - $1.11 Million	-167,217 Reduced 86.54%	26,016 $160,000
Q2 2022 Aug 11, 2022	BUY	$2.11 - $4.06 $215,521 - $414,700	102,143 Added 112.13%	193,233 $728,000
Q1 2022 May 11, 2022	BUY	$2.73 - $11.94 $47,911 - $209,547	17,550 Added 23.86%	91,090 $249,000
Q4 2021 Feb 10, 2022	BUY	$11.49 - $22.0 $28,299 - $54,186	2,463 Added 3.47%	73,540 $845,000
Q3 2021 Nov 12, 2021	BUY	$16.35 - $23.4 $1.16 Million - $1.66 Million	71,077 New	71,077 $1.32 Million

Others Institutions Holding ANNX

# of Institutions

138

Shares Held

87.3M

Call Options Held

2.54M

Put Options Held

556K

View Full List

About Annexon, Inc.

Ticker ANNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,617,700
Market Cap $230M
Description
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated n...

More about ANNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Annexon, Inc. Transaction History